Novo Nordisk A/S stopped two more trials for its experimental heart disease medicine, in a further blow to the drug’s prospects.

Sept 7 (Reuters) - Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ...

Novo Nordisk is downgraded to Hold as GLP-1 franchise strength is offset by pipeline setbacks and growth normalization. Click here to read more on NVO stock.

Novo Nordisk has halted two more ziltivekimab trials in heart failure after a data monitor found limited likelihood of success, adding to the earlier ZEUS setback and leaving only the post‑myocardial ...

Novo Nordisk (NVO) has halted two late-stage trials of its experimental heart drug ziltivekimab, adding to the drugmaker’s recent pipeline setbacks. The Danish company said on Monday that an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

According to a report on September 7, 2026, Novo Nordisk announced that it has halted two additional clinical trials of its experimental cardiovascular drug ziltivekimab due to lack of efficacy, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Novo Nordisk halts two more ziltivekimab heart-failure trials after a data monitor found limited likelihood of success, leaving only the ARTEMIS post-MI study active. Novo Nordisk's STEP Young trial ...

On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker’s ...